Efficacy and safety of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials

BackgroundOlaparib has been proven for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This meta-analysis aims to comprehensively evaluate the efficacy and safety of the combination of olaparib and abiraterone in patients with mCRPC.MethodsThe literature in PubMed, Embase,...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Zhanyang Luo, Bukun Zhu, Hong Xu, Lixin Chen, Xiaoyun Song, Yu Wang, Rui Wang, Jinzhou Zheng, Yunhua Qiu, Jianfeng Yang, Youyang Shi
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Frontiers Media S.A. 2023-10-01
Cyfres:	Frontiers in Oncology
Pynciau:	olaparib abiraterone metastatic castration-resistant prostate cancer (mCRPC) efficacy safety meta-analysis
Mynediad Ar-lein:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1265276/full
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!